Publication:
BRN2 is a non-canonical melanoma tumor-suppressor

dc.contributor.authorMichael Hammen_US
dc.contributor.authorPierre Sohieren_US
dc.contributor.authorValérie Petiten_US
dc.contributor.authorJérémy H. Raymonden_US
dc.contributor.authorVéronique Delmasen_US
dc.contributor.authorMadeleine Le Cozen_US
dc.contributor.authorFranck Gesberten_US
dc.contributor.authorColin Kennyen_US
dc.contributor.authorZackie Aktaryen_US
dc.contributor.authorMarie Pouteauxen_US
dc.contributor.authorFlorian Rambowen_US
dc.contributor.authorAlain Sarasinen_US
dc.contributor.authorNisamanee Charoenchonen_US
dc.contributor.authorAlfonso Bellacosaen_US
dc.contributor.authorLuis Sanchez-del-Campoen_US
dc.contributor.authorLaura Mosteoen_US
dc.contributor.authorMartin Laussen_US
dc.contributor.authorDies Meijeren_US
dc.contributor.authorEirikur Steingrimssonen_US
dc.contributor.authorGöran B. Jönssonen_US
dc.contributor.authorRobert A. Cornellen_US
dc.contributor.authorIrwin Davidsonen_US
dc.contributor.authorColin R. Godingen_US
dc.contributor.authorLionel Larueen_US
dc.contributor.otherUniversité PSLen_US
dc.contributor.otherUniversite Paris-Saclayen_US
dc.contributor.otherLæknadeild Háskóla Íslandsen_US
dc.contributor.otherInstitut de Cancerologie Gustave Roussyen_US
dc.contributor.otherThe University of Edinburghen_US
dc.contributor.otherSkånes universitetssjukhusen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherUniversity of Iowa Carver College of Medicineen_US
dc.contributor.otherFox Chase Cancer Centeren_US
dc.contributor.otherNuffield Department of Medicineen_US
dc.contributor.otherCNRS Centre National de la Recherche Scientifiqueen_US
dc.contributor.otherEquipe Labellisée Ligue Contre le Canceren_US
dc.date.accessioned2022-08-04T08:03:29Z
dc.date.available2022-08-04T08:03:29Z
dc.date.issued2021-12-01en_US
dc.description.abstractWhile the major drivers of melanoma initiation, including activation of NRAS/BRAF and loss of PTEN or CDKN2A, have been identified, the role of key transcription factors that impose altered transcriptional states in response to deregulated signaling is not well understood. The POU domain transcription factor BRN2 is a key regulator of melanoma invasion, yet its role in melanoma initiation remains unknown. Here, in a BrafV600EPtenF/+ context, we show that BRN2 haplo-insufficiency promotes melanoma initiation and metastasis. However, metastatic colonization is less efficient in the absence of Brn2. Mechanistically, BRN2 directly induces PTEN expression and in consequence represses PI3K signaling. Moreover, MITF, a BRN2 target, represses PTEN transcription. Collectively, our results suggest that on a PTEN heterozygous background somatic deletion of one BRN2 allele and temporal regulation of the other allele elicits melanoma initiation and progression.en_US
dc.identifier.citationNature Communications. Vol.12, No.1 (2021)en_US
dc.identifier.doi10.1038/s41467-021-23973-5en_US
dc.identifier.issn20411723en_US
dc.identifier.other2-s2.0-85108003528en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/75932
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85108003528&origin=inwarden_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.subjectChemistryen_US
dc.subjectPhysics and Astronomyen_US
dc.titleBRN2 is a non-canonical melanoma tumor-suppressoren_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85108003528&origin=inwarden_US

Files

Collections